Acazicolcept

Acazicolcept
Clinical data
Other namesALPN-101
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII
KEGG
ChEMBL

Acazicolcept (ALPN-101) is an experimental dual CD28/ICOS antagonist developed by AbbVie.[1][2][3] It appears to be a peptide with 363 residues.[4]

References

  1. ^ Yang, Jing; Lickliter, Jason D.; Hillson, Jan L.; Means, Gary D.; Sanderson, Russell J.; Carley, Kay; Tercero, Almudena; Manjarrez, Kristi L.; Wiley, Jennifer R.; Peng, Stanford L. (July 2021). "First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects". Clinical and Translational Science. 14 (4): 1314–1326. doi:10.1111/cts.12983. PMC 8301585. PMID 33503289.
  2. ^ Dillon, Stacey R.; Evans, Lawrence S.; Lewis, Katherine E.; Debrot, Susan; Blair, Tiffany C.; Mudri, Sherri; Kleist, Kayla; Levin, Steven D.; Bhandari, Janhavi G.; Garrett, Logan; Wolfson, Martin F.; Holland, Pamela M.; Rixon, Mark W.; Peng, Stanford L. (August 2023). "Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept ( ALPN -101)". Arthritis & Rheumatology. 75 (8): 1344–1356. doi:10.1002/art.42484. PMID 36862144. S2CID 257282413.
  3. ^ Orvain, Cindy; Cauvet, Anne; Prudent, Alexis; Guignabert, Christophe; Thuillet, Raphaël; Ottaviani, Mina; Tu, Ly; Duhalde, Fanny; Nicco, Carole; Batteux, Frédéric; Avouac, Jérôme; Wang, NingXin; Seaberg, Michelle A.; Dillon, Stacey R.; Allanore, Yannick (5 January 2022). "Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models". Arthritis Research & Therapy. 24 (1): 13. doi:10.1186/s13075-021-02709-2. PMC 8728910. PMID 34986869.
  4. ^ "KEGG DRUG: Acazicolcept". www.genome.jp.


Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.